Lamotrigine is widely regarded as the mood stabilizer with the most favorable safety profile. It doesn’t cause weight gain, doesn’t produce significant sedation, has no impact on sexual function, and preserves cognitive sharpness better than other options. That said, “safest” depends on what risks matter most to you, because every mood stabilizer carries a different set of trade-offs.
Why Lamotrigine Tops the Safety List
Lamotrigine stands out because it avoids the side effects that make other mood stabilizers hard to live with. Clinical data show it is not associated with weight gain, sexual side effects, or withdrawal symptoms. It also doesn’t destabilize mood in the way some treatments can, where treating depression triggers mania or vice versa.
Cognitively, lamotrigine performs better than every other commonly used mood stabilizer. In a cross-sectional study comparing psychomotor speed, memory, attention, and executive functioning, patients on lamotrigine had the highest performance, followed by those on lithium, valproic acid, and carbamazepine. A separate six-month study found lamotrigine users scored better on verbal fluency and verbal memory tasks compared to those on valproic acid or carbamazepine. For people who describe “brain fog” as one of their biggest concerns with medication, this distinction matters.
The one serious risk with lamotrigine is a rare but potentially dangerous skin reaction called Stevens-Johnson syndrome. Across more than 18,000 patients in randomized controlled trials, this occurred in 0.04% of cases. The risk is even lower in bipolar patients specifically (0.02%). This reaction is tied to how quickly the dose is increased, which is why lamotrigine is always started at a low dose and raised gradually over several weeks. If you develop a rash while starting lamotrigine, your prescriber will likely stop the medication immediately as a precaution.
Lithium: Effective but Requires Monitoring
Lithium remains the gold standard for preventing manic episodes and reducing suicide risk in bipolar disorder. Its effectiveness is hard to match. But it comes with safety concerns that require ongoing blood work and vigilance.
The two major long-term risks are kidney damage and thyroid dysfunction. In a large study published in JAMA Network Open, about 10.8 per 1,000 person-years of lithium use led to stage 3 or higher chronic kidney disease, and about 25.7 per 1,000 person-years led to hypothyroidism (an underactive thyroid). Neither of these is guaranteed, but both require regular monitoring through blood tests, typically every few months.
Weight gain is also common. About 77% of lithium-treated patients gain some weight, with an average gain of 6.3 kg (roughly 14 pounds) in one study. Around 20% of patients report gaining more than 10 kg (22 pounds). A more recent meta-analysis found a smaller average gain, so individual responses vary widely. On the cognitive side, lithium can cause some learning and memory difficulties in the short term, though a six-year follow-up study found that long-term use did not produce lasting cognitive harm.
Valproic Acid: Greater Risk for Certain Groups
Valproic acid (also sold as valproate or divalproex) is effective for mania but carries a heavier side-effect burden than lamotrigine or lithium in several areas.
Weight gain is a significant issue. One study found that 57% of adults on valproic acid gained more than 4 kg, and a more recent study put that figure at 70%. The weight gain tends to be sustained rather than temporary. The drug may drive this by affecting insulin signaling and fat metabolism, leading to increased insulin resistance over time.
Liver toxicity is a well-documented risk. Between 5% and 10% of patients develop elevated liver enzymes during treatment, though these often resolve on their own. Severe liver failure is rare in adults (roughly 1 in 30,000), but the risk climbs dramatically in children under two, especially those on multiple anticonvulsants (about 1 in 600). More than 100 fatal cases of liver injury from valproic acid have been reported in the medical literature. People with certain genetic mutations affecting mitochondrial DNA are at particularly high risk.
Cognitively, valproic acid performs worse than lamotrigine and lithium on measures of memory, attention, and verbal fluency. Carbamazepine, another anticonvulsant sometimes used as a mood stabilizer, shows a similar cognitive profile.
Atypical Antipsychotics as Mood Stabilizers
Several newer antipsychotic medications are approved for bipolar disorder and function as mood stabilizers. Their safety profiles vary enormously from one drug to the next.
Olanzapine and clozapine sit at the riskier end. Both are linked to the greatest increases in weight and blood glucose levels among all atypical antipsychotics. Olanzapine shows the most weight gain after extended use (around 38 weeks in one meta-analysis). These metabolic changes raise the long-term risk of diabetes and cardiovascular disease.
Quetiapine is a middle-ground option. It causes more sedation and weight gain than lamotrigine but performs reasonably well on cognitive measures. In studies, quetiapine-treated patients scored higher on certain memory tasks than those on olanzapine or risperidone, though they still showed some deficits in executive functioning and working memory compared to healthy controls.
Lurasidone and aripiprazole tend to cause less weight gain than olanzapine or quetiapine, making them worth considering if metabolic side effects are a primary concern. However, aripiprazole and risperidone are more likely to cause akathisia, a restless, uncomfortable feeling that makes it difficult to sit still. In pediatric patients, the risk of significant weight gain (7% or more of body weight) is higher across the board than in adults.
Safety During Pregnancy
If pregnancy is a consideration, the safety picture shifts significantly. A large network meta-analysis of congenital malformations ranked lamotrigine as the safest traditional mood stabilizer during pregnancy. Its malformation rates were statistically similar to those in women who took no medication at all.
Among all drugs used for mood stabilization (including antipsychotics), quetiapine and lurasidone ranked alongside lamotrigine for the lowest risk of birth defects. Lithium, by contrast, significantly increased the risk of congenital malformations compared to no treatment. Valproic acid is well established as the most harmful mood stabilizer during pregnancy, and carbamazepine also carries elevated risk.
How “Safest” Depends on Your Situation
Lamotrigine is the closest thing to a consensus answer for the safest mood stabilizer overall. It spares your weight, your cognition, your metabolism, and your sexual function in ways that other options simply don’t. Its primary limitation is that it works better for preventing depressive episodes than manic ones, so people whose bipolar disorder is dominated by mania may need a different drug or a combination.
Lithium remains the best-proven option for severe mania and suicide prevention, and its risks are manageable with regular blood monitoring. Valproic acid is effective for mania but harder to justify as a first choice given its weight, liver, and cognitive effects. Among atypical antipsychotics, quetiapine and lurasidone offer reasonable safety profiles, while olanzapine carries the heaviest metabolic cost. The right choice balances which symptoms need treating, which side effects you’re most willing to tolerate, and whether pregnancy is part of the picture now or in the future.